Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DX5EBI
|
||||
Drug Name |
5-(3-(4-(4-methylpiperazin-1-yl)phenyl)prop-1-ynyl)-4-(neopentylamino)pyrimidine-2-carbonitrile
|
||||
Synonyms |
CHEMBL259939
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C24H30N6
|
||||
Canonical SMILES |
CN1CCN(CC1)c2ccc(CC#Cc3cnc(nc3NCC(C)(C)C)C#N)cc2
|
||||
InChI |
InChI=1S/C24H30N6/c1-24(2,3)18-27-23-20(17-26-22(16-25)28-23)7-5-6-19-8-10-21(11-9-19)30-14-12-29(4)13-15-30/h8-11,17H,6,12-15,18H2,1-4H3,(H,26,27,28)
|
||||
InChIKey |
RVYUARIENPNTJS-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Cathepsin K | Target Info | [1587926] | ||
Cathepsin L | Target Info | [1587926] | |||
Reactome | Collagen degradation | ||||
Degradation of the extracellular matrix | |||||
Activation of Matrix Metalloproteinases | |||||
Trafficking and processing of endosomal TLR | |||||
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
Assembly of collagen fibrils and other multimeric structures | |||||
MHC class II antigen presentation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.